Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy.
about
Posttranslational Modifications and the Immunogenicity of BiotherapeuticsAlzheimer's disease--a panorama glimpsePurification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid-β Variants and Structural Analysis by Solution NMR SpectroscopyStructural Analysis and Aggregation Propensity of Pyroglutamate Aβ(3-40) in Aqueous TrifluoroethanolA retrospective analysis of the Alzheimer's disease vaccine progress - The critical need for new development strategies.Pyroglutamate-Modified Amyloid-β(3-42) Shows α-Helical Intermediates before Amyloid Formation.Oxidative stress and mitochondria-mediated cell death mechanisms triggered by the familial Danish dementia ADan amyloidpGluAβ increases accumulation of Aβ in vivo and exacerbates its toxicity.Posttranslational modification impact on the mechanism by which amyloid-β induces synaptic dysfunction.Isotope-edited FTIR reveals distinct aggregation and structural behaviors of unmodified and pyroglutamylated amyloid β peptides.Disturbance of Plasma Lipid Metabolic Profile in Guillain-Barre Syndrome.Plant-based chimeric HPV-virus-like particles bearing amyloid-β epitopes elicit antibodies able to recognize amyloid plaques in APP-tg mouse and Alzheimer's disease brains.APP/Aβ structural diversity and Alzheimer's disease pathogenesis.Aβ truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition.Comprehensive Characterization of the Pyroglutamate Amyloid-β Induced Motor Neurodegenerative Phenotype of TBA2.1 Mice.Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease.
P2860
Q26748614-909F73AD-D87B-4785-B6DE-791BBE5ACE20Q27011749-304AD821-8C94-4F8B-8FBA-CBA4DD63AD51Q28550062-1EFD21E5-CCF4-4168-B879-DF260FB9AF36Q28551142-B4BF8C23-6E03-4ADD-B9DD-587A1D154476Q34518856-09503ABB-D27C-40DB-A49A-21A415219317Q36356545-0C7576B8-BB25-45D0-8DDF-45566BB20758Q36396174-F56EBE1E-6899-4435-BD5E-4FFDB3F6ED46Q37322106-2FD09913-ED52-4D54-9802-93EE092AB04AQ38831521-9D87E624-A08C-474C-A2E0-E5C5BD5BC2EFQ40692757-170EEFB3-8B72-4D7A-B218-1EF104808912Q41419380-7FC77C24-C910-43A0-A9DE-7B4826B91D3DQ45325394-34915350-5A74-48AA-9757-E0AA3B7649D0Q46320596-923423BC-EFFD-482B-B591-583E7B9EC35CQ46335422-AA077890-30B1-4FD2-AF64-58767EE9058DQ52341984-5A072C10-FF0F-4C3A-9704-C126F53C1655Q54982684-7E9E80C4-68CD-42D8-B631-32DCD8563EFC
P2860
Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pyroglutamate-Modified Amyloid ...... eimer´s Disease Immunotherapy.
@en
type
label
Pyroglutamate-Modified Amyloid ...... eimer´s Disease Immunotherapy.
@en
prefLabel
Pyroglutamate-Modified Amyloid ...... eimer´s Disease Immunotherapy.
@en
P2860
P1476
Pyroglutamate-Modified Amyloid ...... eimer´s Disease Immunotherapy.
@en
P2093
Goar Gevorkian
Roxanna Perez-Garmendia
P2860
P304
P356
10.2174/1570159X11311050004
P577
2013-09-01T00:00:00Z